Cipla to launch respiratory inhaler Synchrobreathe for asthma

Cipla will soon launch an innovative inhaler, called Synchrobreathe, which will bring important benefits for physicians, patients and healthcare providers on managing Obstructive Airway Disease (OAD). Synchrobreathe is a novel, breath-actuated inhaler (BAI) with a dose counter.
 
Frank Pieters, global head of respiratory for Cipla, said, “Simple and intuitive, Synchrobreathe is an innovation in managing respiratory disease. Synchrobreathe is attractive for patients as the inhaler is easy to use effectively. Equally importantly, Synchrobreathe will help cut the time healthcare providers need to spend to train patients in correct inhaler use. With this simple inhaler, the healthcare professional knows the patient will be able to use it easily and get the full benefit from every dose.”